PMID- 24100259
OWN - NLM
STAT- MEDLINE
DCOM- 20140716
LR  - 20151119
IS  - 1536-3686 (Electronic)
IS  - 1075-2765 (Linking)
VI  - 20
IP  - 6
DP  - 2013 Nov-Dec
TI  - Age and gender as predictors of benefit from aminophylline administration in 
      patients undergoing regadenoson stress myocardial perfusion imaging: a substudy 
      of the ASSUAGE trial.
PG  - 622-9
LID - 10.1097/01.mjt.0000434986.92593.8b [doi]
AB  - Regadenoson is a selective adenosine A2A-receptor agonist, used as a 
      pharmacological stress agent for myocardial perfusion imaging. It is associated 
      with frequent adverse effects (AEs), particularly among individuals younger than 
      65 years of age and women. Intravenous aminophylline administration following 
      regadenoson, as described in the ASSUAGE trial, reduces the incidence of AE. In 
      this substudy of the ASSUAGE trial, we compared the absolute and relative 
      benefits of aminophylline administration versus placebo, between subgroups of age 
      (<65 vs. >/=65 years) and gender (women vs. men). Study endpoints were headache, 
      gastrointestinal AE, any regadenoson AE, and tolerability (feeling comfortable 
      during regadenoson stress). Among patients <65years, compared with >/=65 years, 
      aminophylline administration was associated with greater absolute risk reduction 
      (ARR) in gastrointestinal AE (16% vs. 5%, P = 0.01) and any regadenoson AE (31% 
      vs. 12%, P = 0.001), and with a greater absolute improvement in tolerability (21% 
      vs. 1%, P < 0.001). Men received greater ARR in gastrointestinal AE than women 
      (18% vs. 2%, P < 0.001). There was no difference in the ARR in other AE between 
      subgroups. Across all subgroups, aminophylline use was associated with a 
      consistent trend toward relative reduction in AE rates and improved tolerability. 
      No significant interaction was identified between subgroups and aminophylline 
      administration in reducing AE. In conclusion, although aminophylline use was 
      associated with greater ARR in AE in certain subgroups, a consistent benefit with 
      aminophylline administration was attained in all subgroups. Thus, to predictably 
      reduce regadenoson AE and improve tolerability, aminophylline should be 
      administered routinely to all patients as per the ASSUAGE protocol.
FAU - Rangel, Maria O
AU  - Rangel MO
AD  - 1Division of Cardiology, Rush University Medical Center, Chicago, IL; 2Department 
      of Pediatrics, University of Illinois Hospital and Health System, Chicago, IL; 
      and 3Division of Adult Cardiology, John H. Stroger, Jr. Hospital of Cook County, 
      Chicago, IL.
FAU - Demori, Raysa Morales
AU  - Demori RM
FAU - Doukky, Rami
AU  - Doukky R
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - United States
TA  - Am J Ther
JT  - American journal of therapeutics
JID - 9441347
RN  - 0 (Adenosine A2 Receptor Agonists)
RN  - 0 (Purinergic P1 Receptor Antagonists)
RN  - 0 (Purines)
RN  - 0 (Pyrazoles)
RN  - 27Y3KJK423 (Aminophylline)
RN  - 2XLN4Y044H (regadenoson)
SB  - IM
MH  - *Adenosine A2 Receptor Agonists/adverse effects
MH  - Administration, Intravenous
MH  - Age Factors
MH  - Aged
MH  - Aminophylline/*administration & dosage
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Perfusion Imaging/*methods
MH  - Purinergic P1 Receptor Antagonists/administration & dosage
MH  - *Purines/adverse effects
MH  - *Pyrazoles/adverse effects
MH  - Risk
MH  - Sex Factors
EDAT- 2013/10/09 06:00
MHDA- 2014/07/17 06:00
CRDT- 2013/10/09 06:00
PHST- 2013/10/09 06:00 [entrez]
PHST- 2013/10/09 06:00 [pubmed]
PHST- 2014/07/17 06:00 [medline]
AID - 10.1097/01.mjt.0000434986.92593.8b [doi]
PST - ppublish
SO  - Am J Ther. 2013 Nov-Dec;20(6):622-9. doi: 10.1097/01.mjt.0000434986.92593.8b.